Tag: Stempeutics
Stempeucel-OA demonstrates durable 24-month efficacy & cartilage preservation in phase 3...
Peer-reviewed results published in Osteoarthritis and Cartilage Open show significant improvements in pain, function, and structural outcomes versus placebo
Cipla partners with Stempeutics, launches stem cell therapy for knee osteoarthritis
Ciplostem is a disease-modifying approach that slows down disease progression and promotes cartilage maintenance, thereby offering long-term pain relief for Grade II and III Knee OA
Stempeutics phase 3 cell therapy trial for Diabetic Foot Ulcer completes...
Stempeucel®-DFU - a stem cell therapy product, promises significant therapeutic effect due to its strong angiogenic and anti-inflammatory properties
Stempeucel, first ‘Made in India’ cell therapy to treat Critical Limb...
Developed by Stempeutics over a period of twelve years, the breakthrough treatment designed to address the root cause of Critical Limb Ischemia at an affordable cost will be marketed and distributed in India by Cipla.....................
Stempeutics sells marketing rights for its stem cell therapy product to...
Under this agreement, Alkem will get the exclusive marketing rights for Stempeucel in India for Osteoarthritis with Stempeutics manufacturing and supplying the product to the company.............
BioVoice eMag April 2017 Issue-11 Volume-1
BioVoice eMag April 2017 Issue-11 Volume-1:
The ‘April 2017’ issue of BioVoice eMagazine includes the COVER STORY on Biorevolution 2.0: India’s quest to become a biotech...
Empowering Indian bioentrepreneurs to be globally competitive
Pushpa Vijayraghavan, Vice President, Sathguru Inc lists out the way forward for India’s bioscience entrepreneurs...